Hims & Hers advertised a $49 Wegovy lookalike pill Thursday -- then on Saturday said it won't sell it. Both the FDA and Novo Nordisk have objected to what Hims & Hers is doing. Over the weekend, ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Novo Nordisk NOVO.B1.58%increase; green up pointing triangle accused Hims & Hers of “illegal mass compounding” after the telehealth platform said it would offer a cheaper, compounded version of the ...

Novo Nordisk said it will take legal action again telehealth provider Hims & Hers after Hims announced a cheaper copycat version of Novo's Wegovy weight loss pill. Hims said it would sell a copy of ...

Before the audience in Davos, President Donald Trump repeated a claim on Wednesday that he's said before -- that the Russian war on Ukraine "wouldn't have started" if the 2020 U.S. presidential ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has taken the other side of the deal, acquiring rights to the assets and giving ...

LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" start after its launch this month, analysts said on Friday citing early U.S. prescription data, with the ...

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday. Wegovy’s once-daily pill, an oral spinoff of its ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk plans to ...

As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...

SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...